Assessment Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Indication: Together with chemotherapy, with the treatment of adult patients with locally recurrent unresectable or metastatic triple-damaging breast cancer who have not obtained prior chemotherapy for metastatic condition and whose tumours express programmed cell Demise-ligand one (mixed positive rating ≥ 10) as based on https://gregorywsldu.therainblog.com/34857689/helping-the-others-realize-the-advantages-of-keytruda-cost